Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004461 | Eclampsia NIH | 1.00 |
| D011225 | Pre-Eclampsia NIH | 0.71 |
| D046110 | Hypertension, Pregnancy-Induced NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100601 | Eclampsia HPO | 1.00 |
| HP:0100603 | Toxemia of pregnancy HPO | 0.71 |
| HP:0000822 | Hypertension HPO | 0.20 |
Navigate: Correlations HPO
There is one clinical trial.
Hypertensive disorders of pregnancy (HDP) are increasingly recognized sex-specific risk factors for premature cardiovascular disease (CVD) in women. HDP, including preeclampsia and gestational hypertension, confer a 2- to 3-fold increase in the risk of chronic hypertension and ischemic heart disease 10-15 years after delivery. Observational data suggest that breastfeeding can lower maternal blood pressure (BP), risk of metabolic syndrome, and other markers of cardiovascular risk in the short term and long term, possibly by helping to re-set the metabolic changes of pregnancy. We recently demonstrated an 11% reduction in the risk of metabolic syndrome among postpartum women with a variety of complications in pregnancy, including HDP, who breastfed for > 6 months, compared to those who did not breastfeed and those who breastfed for shorter durations. An analysis of 622 postpartum women at Kingston General Hospital showed that breastfeeding women had nearly a 6-mmHg lower systolic BP than women who did not breastfeed with an apparent dose-response effect of breastfeeding duration. Women with pregnancy complications including HDP are vulnerable to early weaning. Interactive, multi-modal approaches targeting a mother's breastfeeding self-efficacy (i.e., confidence about breastfeeding) have been effective in healthy postpartum women. However, breastfeeding support interventions have not yet been tested specifically in HDP women, who stand to derive substantial benefit from breastfeeding. This is an important area to study since nurse-led breastfeeding supportive interventions can be widely applied to the postpartum care of women with HDP and can be integrated into comprehensive CVD risk reduction programs for these women. Our primary outcome is postpartum BP, since hypertension is a key mediating factor in women's heart health. We conducted a feasibility study of a breastfeeding self-efficacy intervention to enhance breastfeeding outcomes among women with HDP showing feasibility (achieving pre-defined targets of a recruitment rate of >50% , attrition rates of < 30%), and > 70% participant satisfaction with the intervention, measured at the 6-month time point. Additionally, data showed trends in both systolic and diastolic BP favoring the intervention group. We are now conducting a multi-site open-label randomized trial to assess for a difference in blood pressure and breastfeeding between groups, and to serve as a cohort of HDP women for longitudinal follow-up.
Description: Evaluate whether a nurse-led BSE intervention will result in a lower systolic and/or diastolic BP 12 months postpartum
Measure: Systolic and/or diastolic BP, in mmHg. Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in a lower need for antihypertensive therapy
Measure: Use of antihypertensive therapy Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in longer duration of exclusive breastfeeding
Measure: Duration of exclusive breastfeeding (weeks) Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in higher rates of any continued breastfeeding at 6 months
Measure: The proportion who breastfeed (exclusive or non-exclusive) Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in lower metabolic syndrome
Measure: Metabolic syndrome Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports